Related Experiment Videos
Reappraisal of GLP-1 receptor agonists in older adults
Giuseppe Maltese1, Theocharis Koufakis2, Djordje S Popovic3
1Department of Diabetes and Endocrinology, Epsom and St Helier University Hospitals, Surrey SM5 1AA, UK; Unit for Metabolic Medicine, Cardiovascular Division, Faculty of Life Sciences & Medicine, King's College London, London WC2R 2LS, UK.
Abstract:
Glucagon-like peptide-1 receptor agonists are transforming cardiometabolic care, yet their expanding use in older adults raises an overlooked question: can cardiovascular and renal protection come at the expense of muscle mass, nutritional resilience, and independence? We propose a geriatric-informed prescribing framework that redefines treatment success beyond weight loss.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Pharmacodynamics in Geriatric Patients: Effects of Age
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Drug Dosing: Geriatric Patients
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Oral Hypoglycemic Agents: Glinides